tetano
Editor, Senior Moderator
Clin Infect Dis
. 2023 May 24;76(10):1872-1874.
doi: 10.1093/cid/ciad090. Longitudinal Whole-Genome Sequence Characterization of a Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.5 Infection in an Immunocompromised Patient Successfully Treated With Sotrovimab 1000 mg
Francisco Tejerina[SUP] 1 2 [/SUP], Rosalía Palomino[SUP] 3 [/SUP], Pilar Catalan[SUP] 1 [/SUP], Amadeo Sanz[SUP] 3 [/SUP], Mercedes Marin[SUP] 1 [/SUP], Felipe Lopez-Andujar[SUP] 1 [/SUP], Leire Perez[SUP] 1 2 [/SUP], Teresa Aldamiz[SUP] 1 2 [/SUP], Patricia Muñoz[SUP] 1 4 5 [/SUP], Carmen Rodriguez-Gonzalez[SUP] 6 [/SUP], Cristina Diez[SUP] 1 2 [/SUP], Chiara Fanciulli[SUP] 1 2 [/SUP], Laura Pérez Lago[SUP] 1 3 [/SUP], Darío García de Viedma[SUP] 1 3 5 [/SUP]
Affiliations
Conflict of interest statement
Potential conflicts of interest . C. R.-G. reports payment or honoraria from Viiv Healthcare, Pfizer, and BD. P. M. reports consulting fees, payment or honoraria, and payment for expert testimony from Gilead and Mundipharma, participation on a Data Safety Monitoring or Advisory Board for Gilead, and support for attending meetings and/or travel from Pfizer. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
. 2023 May 24;76(10):1872-1874.
doi: 10.1093/cid/ciad090. Longitudinal Whole-Genome Sequence Characterization of a Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.5 Infection in an Immunocompromised Patient Successfully Treated With Sotrovimab 1000 mg
Francisco Tejerina[SUP] 1 2 [/SUP], Rosalía Palomino[SUP] 3 [/SUP], Pilar Catalan[SUP] 1 [/SUP], Amadeo Sanz[SUP] 3 [/SUP], Mercedes Marin[SUP] 1 [/SUP], Felipe Lopez-Andujar[SUP] 1 [/SUP], Leire Perez[SUP] 1 2 [/SUP], Teresa Aldamiz[SUP] 1 2 [/SUP], Patricia Muñoz[SUP] 1 4 5 [/SUP], Carmen Rodriguez-Gonzalez[SUP] 6 [/SUP], Cristina Diez[SUP] 1 2 [/SUP], Chiara Fanciulli[SUP] 1 2 [/SUP], Laura Pérez Lago[SUP] 1 3 [/SUP], Darío García de Viedma[SUP] 1 3 5 [/SUP]
Affiliations
- PMID: 37253129
- DOI: 10.1093/cid/ciad090
Conflict of interest statement
Potential conflicts of interest . C. R.-G. reports payment or honoraria from Viiv Healthcare, Pfizer, and BD. P. M. reports consulting fees, payment or honoraria, and payment for expert testimony from Gilead and Mundipharma, participation on a Data Safety Monitoring or Advisory Board for Gilead, and support for attending meetings and/or travel from Pfizer. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.